Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2022
2021
2020
Profitability Metrics
Gross Margin
60.37%
Operating Margin
89.69%
Net Margin
67.50%
Efficiency Metrics
Revenue per Expense Ratio
9.70
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
-4.05%
Income Tax Rate
0.00%
EPS
0.3300000000
Balance Sheet Analysis
Current Ratio
0.07
Cash Ratio
0.00
Working Capital
$-195.50M
Debt to Equity
0.44
Debt to Assets
29.25%
Equity Ratio
66.27%
Cash Flow Analysis
Operating Cash Flow Ratio
-282.47%
Free Cash Flow Ratio
-282.47%
CapEx to Revenue
0.00%
Dividends Paid
$39.20M
Stock Buybacks
$22.17K
Total Shareholder Returns
$39.22M
Cash Position Change
-89.05%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Detailed Growth Metrics
Core Performance
Revenue
246.09%
Net Income
196.04%
EPS
170.21%
Operating Income
1.00%
Operational Efficiency
R&D Expenses
-100.00%
SG&A Expenses
672.54%
Operating Cash Flow
-309.68%
Free Cash Flow
-309.68%
Balance Sheet Health
Assets
36.68%
Debt
46.26%
Book Value per Share
-7.20%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
-23.18%
Shares Outstanding
39.03%
Long Term Trends
3Y Revenue/Share
-67.24%
5Y Revenue/Share
10.57%
3Y Dividend/Share
-17.92%
5Y Dividend/Share
-16.71%